Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0026986 (
myelodysplastic syndrome
)
14,926
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
LYL1
gene encodes a basic helix-loop-helix transcription factor involved in T-cell acute lymphoblastic leukemia. Using real-time quantitative RT-PCR assay, we found that the expression of
LYL1
was at higher levels in the majority cases of acute myeloblastic leukemia (AML) or
myelodysplastic syndrome
when compared to normal bone marrow. Our study also showed that
LYL1
was highly expressed in most AML cell lines and in CD34+ AML cells. To determine whether
LYL1
had an affect on the phenotype and behavior of myeloid cells, we introduced full-length
LYL1
cDNA into K562 cells using electroporation and U937 cells with retroviral infection. Both of the derivative cell lines with overexpression of
LYL1
had an increased growth rate and clonogenecity. Forced expression of
LYL1
in K562 cells enhanced spontaneous and hemin-induced erythroid differentiation but blocked spontaneous as well as PMA-induced megakaryocytic differentiation. Overexpression of
LYL1
in U937 cells blocked all-trans retinoic acid-induced monocytic differentiation. The
LYL1
-transfected U937 cells were also more resistant to the cytotoxic drug cytarabine. These results demonstrate that
LYL1
may play a role in early hematopoiesis and may be a potential oncogenic factor in AML.
...
PMID:Oncogenic potential of the transcription factor LYL1 in acute myeloblastic leukemia. 1609 22